Patents Assigned to SHANGHAI DE NOVO PHARMATECH CO LTD.
-
Patent number: 11248006Abstract: A macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one as represented by formula (I) and/or a pharmaceutically acceptable salt thereof, a composition comprising the compound as represented by formula (I) and/or a pharmaceutically acceptable salt thereof, a preparation method therefor, use thereof as a Wee1 inhibitor and use thereof as a sensitizer in chemotherapy or a radiotherapy of cancers. The macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one can effectively inhibit Wee1 and relating signaling pathways, having good therapeutic and relieving effects on cancers.Type: GrantFiled: March 21, 2018Date of Patent: February 15, 2022Assignee: SHANGHAI DE NOVO PHARMATECH CO., LTD.Inventors: Zhiming Zhao, Daxin Gao, Shoujun Chen, Zhiheng Wu
-
Patent number: 10669252Abstract: Disclosed are a benzazepine derivative, a preparation method, a pharmaceutical composition and the use thereof. A compound as shown in formula (I) of the present invention, and an isomer, a prodrug, a stable isotope derivative or a pharmaceutically acceptable salt thereof have the following structure. The benzazepine derivative of the present invention has a good regulation effect on the TLR family and the related signaling pathway, and in particular, has a good regulation effect on TLR8, can effectively treat, relieve and/or prevent various diseases mediated by TLR family and the TLR-related signaling pathway, and in particular, can effectively treat, relieve and/or prevent various diseases mediated by TLR8, such as cancers, autoimmune diseases, infections, inflammations, transplantation rejections, graft-versus-host diseases, etc.Type: GrantFiled: May 4, 2017Date of Patent: June 2, 2020Assignee: SHANGHAI DE NOVO PHARMATECH CO., LTD.Inventors: Daxin Gao, Yuxun Wang, Shoujun Chen, Heping Yang
-
Publication number: 20190152941Abstract: Disclosed are a benzazepine derivative, a preparation method, a pharmaceutical composition and the use thereof. A compound as shown in formula (I) of the present invention, and an isomer, a prodrug, a stable isotope derivative or a pharmaceutically acceptable salt thereof have the following structure. The benzazepine derivative of the present invention has a good regulation effect on the TLR family and the related signaling pathway, and in particular, has a good regulation effect on TLR8, can effectively treat, relieve and/or prevent various diseases mediated by TLR family and the TLR-related signaling pathway, and in particular, can effectively treat, relieve and/or prevent various diseases mediated by TLR8, such as cancers, autoimmune diseases, infections, inflammations, transplantation rejections, graft-versus-host diseases, etc.Type: ApplicationFiled: May 4, 2017Publication date: May 23, 2019Applicant: SHANGHAI DE NOVO PHARMATECH CO., LTD.Inventors: Daxin GAO, Yuxun WANG, Shoujun CHEN, Heping YANG
-
Patent number: 10202388Abstract: This disclosure is related to a fused-ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the fused ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, preparation methods thereof, and use thereof in modulating activity of indoleamine 2, 3-dioxygenase (IDO) and/or tryptophan 2, 3-dioxygenase (TDO). This disclosure further provides methods of treating IDO and/or TDO-associated diseases, including cancer, viral infection and autoimmune diseases.Type: GrantFiled: February 3, 2016Date of Patent: February 12, 2019Assignee: SHANGHAI DE NOVO PHARMATECH CO., LTD.Inventors: Qun Li, Daxin Gao
-
Patent number: 9914724Abstract: This invention relates to a kind of C- aryl glycoside derivatives, its pharmaceutical compositions, preparation methods, and uses thereof. The preparation method comprises: method 1: in a solvent, deprotecting the acetyl protecting groups of compound 1-f in the presence of a base; method 2: 1) compound 2-g reacts with via Mitsunobu reaction; 2) deprotecting the acetyl protecting groups of compound 2-f obtained from step 1; method 3: 1) compound 2-g reacts with via nucleophilic substitution reaction; 2) deprotecting the acetyl protecting groups of compound 3-f obtained from step 1. The pharmaceutical composition comprises a kind of C- aryl glycoside derivatives; it's pharmaceutically acceptable salts and/or prodrugs thereof and excipient thereof. This invention relates to a kind of C- aryl glycoside derivatives, it's pharmaceutically acceptable salts or compositions thereof for preparing a SGLT inhibitor. The C- aryl glycoside derivatives of this invention provides a new direction for SGLT inhibitors.Type: GrantFiled: April 1, 2015Date of Patent: March 13, 2018Assignee: SHANGHAI DE NOVO PHARMATECH CO., LTD.Inventors: Daxin Gao, Heping Yang, Pei Wang
-
Publication number: 20180022752Abstract: This disclosure is related to a fused-ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the fused ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, preparation methods thereof, and use thereof in modulating activity of indoleamine 2, 3-dioxygenase (IDO) and/or tryptophan 2, 3-dioxygenase (TDO). This disclosure further provides methods of treating IDO and/or TDO-associated diseases, including cancer, viral infection and autoimmune diseases.Type: ApplicationFiled: February 3, 2016Publication date: January 25, 2018Applicant: Shanghai De Novo Pharmatech Co., Ltd.Inventors: Qun LI, Daxin GAO
-
Publication number: 20170037038Abstract: This invention relates to a kind of C-aryl glycoside derivatives, its pharmaceutical compositions, preparation methods, and uses thereof. The preparation method comprises: method 1: in a solvent, deprotecting the acetyl protecting groups of compound 1-f in the presence of a base; method 2: 1) compound 2-g reacts with via Mitsunobu reaction; 2) deprotecting the acetyl protecting groups of compound 2-f obtained from step 1; method 3: 1) compound 2-g reacts with via nucleophilic substitution reaction; 2) deprotecting the acetyl protecting groups of compound 3-f obtained from step 1. The pharmaceutical composition comprises a kind of C-aryl glycoside derivatives; it's pharmaceutically acceptable salts and/or prodrugs thereof and excipient thereof. This invention further relates to a kind of C-aryl glycoside derivatives, it's pharmaceutically acceptable salts or pharmaceutical compositions thereof for the use in preparation of a SGLT inhibitor.Type: ApplicationFiled: April 1, 2015Publication date: February 9, 2017Applicant: SHANGHAI DE NOVO PHARMATECH CO. LTD.Inventors: Daxin GAO, Heping YANG, Pei WANG
-
Patent number: 9216997Abstract: The present invention relates to a tri-heterocyclic derivatives, preparation process and uses thereof, specifically relates to a tri-heterocyclic derivatives of the formula (I) or a pharmaceutically acceptable salt thereof, preparation process, and further relates to a pharmaceutically acceptable composition comprising compounds of formula (I), or a pharmaceutically acceptable salt thereof, and their pharmaceutical use as inhibitors of kinase.Type: GrantFiled: December 13, 2012Date of Patent: December 22, 2015Assignee: Shanghai De Novo Pharmatech Co Ltd.Inventors: Daxin Gao, Heping Yang, Yajun Yu
-
Patent number: 8999985Abstract: Disclosed are substituted phthalazin-1 (2H)-ones of the formula (IA), preparation processes and medical uses thereof, particularly related to the compositions containing the same and the uses thereof, more particularly related to their pharmaceutical use as inhibitors of PARP.Type: GrantFiled: December 2, 2010Date of Patent: April 7, 2015Assignee: Shanghai de Novo Pharmatech Co Ltd.Inventor: Daxin Gao
-
Publication number: 20130224107Abstract: Disclosed are heterocyclic derivatives, methods for making them, compositions containing the same and uses thereof. Particularly, their pharmaceutical use as inhibitors of PARP is disclosed.Type: ApplicationFiled: December 2, 2010Publication date: August 29, 2013Applicant: SHANGHAI DE NOVO PHARMATECH CO LTD.Inventor: Daxin Gao